Charity Scripture - Dec 1, 2021 Form 3 Insider Report for BELLICUM PHARMACEUTICALS, INC (BLCM)

Role
Chief Development Officer
Signature
Charity Scripture
Stock symbol
BLCM
Transactions as of
Dec 1, 2021
Transactions value $
$0
Form type
3
Date filed
12/2/2021, 02:21 PM
Next filing
Aug 16, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BLCM Common Stock 14.6K Dec 1, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BLCM Stock Option (right to buy) Dec 1, 2021 Common Stock 2.5K $4.41 Direct F1
holding BLCM Stock Option (right to buy) Dec 1, 2021 Common Stock 19.3K $1.36 Direct F2
holding BLCM Stock Option (right to buy) Dec 1, 2021 Common Stock 20K $7.13 Direct F3
holding BLCM Stock Option (right to buy) Dec 1, 2021 Common Stock 35K $2.97 Direct F4
holding BLCM Stock Option (right to buy) Dec 1, 2021 Common Stock 50K $2.88 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option vest and became exercisable on October 1, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
F2 25% of the shares subject to the stock option vest and became exercisable on February 3, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
F3 100% of the shares subject to the stock option vest and became exercisable on August 3, 2021.
F4 50% of the shares subject to the stock option vest and become exercisable on December 15, 2021, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter.
F5 50% of the shares subject to the stock option vest and become exercisable on August 16, 2022, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter.